CN118176021A - 抗ctla-4抗体给药方案 - Google Patents

抗ctla-4抗体给药方案 Download PDF

Info

Publication number
CN118176021A
CN118176021A CN202280072636.XA CN202280072636A CN118176021A CN 118176021 A CN118176021 A CN 118176021A CN 202280072636 A CN202280072636 A CN 202280072636A CN 118176021 A CN118176021 A CN 118176021A
Authority
CN
China
Prior art keywords
cancer
ctla
antibody
seq
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280072636.XA
Other languages
English (en)
Chinese (zh)
Inventor
Y·刘
P·张
M·戴文波特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Onco Pharmaceuticals
Original Assignee
Onco Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Onco Pharmaceuticals filed Critical Onco Pharmaceuticals
Publication of CN118176021A publication Critical patent/CN118176021A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
CN202280072636.XA 2021-10-29 2022-10-28 抗ctla-4抗体给药方案 Pending CN118176021A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163273660P 2021-10-29 2021-10-29
US63/273,660 2021-10-29
PCT/US2022/078875 WO2023077069A1 (en) 2021-10-29 2022-10-28 Anti-ctla-4 antibody dosing regimens

Publications (1)

Publication Number Publication Date
CN118176021A true CN118176021A (zh) 2024-06-11

Family

ID=86158833

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280072636.XA Pending CN118176021A (zh) 2021-10-29 2022-10-28 抗ctla-4抗体给药方案

Country Status (9)

Country Link
EP (1) EP4422685A4 (https=)
JP (1) JP2024540152A (https=)
KR (1) KR20240099187A (https=)
CN (1) CN118176021A (https=)
AU (1) AU2022377644A1 (https=)
CA (1) CA3234351A1 (https=)
MX (1) MX2024004429A (https=)
TW (1) TW202325738A (https=)
WO (1) WO2023077069A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN121358769A (zh) * 2023-05-17 2026-01-16 昂科医药 Ph敏感性抗ctla-4抗体及其用途
WO2026041780A2 (en) * 2024-08-23 2026-02-26 BioNTech SE Combination therapy comprising anti-ctla4 antibodies and chemotherapy for cancer treatment

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8110194B2 (en) * 2005-12-07 2012-02-07 Medarex, Inc. CTLA-4 antibody dosage escalation regimens
EP2912063A1 (en) * 2012-10-23 2015-09-02 Bristol-Myers Squibb Company Combination of anti-kir and anti-ctla-4 antibodies to treat cancer
PL3142751T3 (pl) * 2014-05-13 2019-12-31 Medimmune Limited Przeciwciała anty-b7-h1 i anty-ctla-4 do leczenia niedrobnokomórkowego nowotworu płuca
ES2979210T3 (es) 2015-12-15 2024-09-24 Oncoc4 Inc Anticuerpos monoclonales anti-CTLA4 humano quiméricos y humanizados y usos de los mismos
TWI799432B (zh) * 2017-07-27 2023-04-21 美商再生元醫藥公司 抗ctla-4抗體及其用途
JP2021513540A (ja) * 2018-02-13 2021-05-27 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． 抗ｐｄ−１抗体及び抗ｃｔｌａ４抗体によるがんの処置方法

Also Published As

Publication number Publication date
MX2024004429A (es) 2024-05-06
EP4422685A1 (en) 2024-09-04
CA3234351A1 (en) 2023-05-04
EP4422685A4 (en) 2025-12-03
AU2022377644A1 (en) 2024-05-16
KR20240099187A (ko) 2024-06-28
JP2024540152A (ja) 2024-10-31
WO2023077069A1 (en) 2023-05-04
TW202325738A (zh) 2023-07-01

Similar Documents

Publication Publication Date Title
TWI780994B (zh) 用於治療非小細胞肺癌之抗b7-h1及抗ctla-4抗體
CN109153723B (zh) 抗pd-1抗体与放射的组合治疗癌症
JP6774421B2 (ja) がんの治療のための方法、組成物、及びキット
TWI912619B (zh) 使用抗ｐｄ-１抗體與抗ｃｔｌａ-４抗體之組合以治療肺癌
ES2951650T3 (es) Uso de un anticuerpo anti-PD-1 junto con un anticuerpo anti-CD30 en el tratamiento del linfoma
US11572405B2 (en) Combination therapy with anti-IL-8 antibodies and anti-PD-1 antibodies for treating cancer
CN114746117B (zh) 抗dll3药剂的给药方案
KR20170007750A (ko) Ｈｐｖ-음성 암의 치료를 위한 ｐｄｌ-1의 길항제 및 ｐｄ-1의 길항제
US12565528B2 (en) LAG-3 antagonist therapy for lung cancer
TWI817958B (zh) 用於治療肝癌之組合物及方法
JP2022184998A (ja) 特定の癌の治療のためのラムシルマブとペンブロリズマブとの組み合わせ
CN114340679A (zh) 用于治疗对pd-1/pd-l1信号传导抑制剂无应答的癌症的方法和药物
CN118176021A (zh) 抗ctla-4抗体给药方案
Kojima et al. Phase I dose‐escalation trial of Sym004, an anti‐EGFR antibody mixture, in Japanese patients with advanced solid tumors
CN119947752A (zh) 抗ctla-4抗体用于治疗腺样囊性癌的用途
JP2023011902A (ja) Ｐｄ－１阻害剤を投与することにより子宮頸がんを処置する方法
WO2022223006A1 (zh) 抗pd-1抗体联合一线化疗治疗晚期非小细胞肺癌的用途
HK40106641A (zh) 抗ctla-4抗体给药方案
HK40112915A (zh) 抗半乳糖凝集素-9抗体及其治疗用途
KR20230159833A (ko) Pd-1 저해제의 투여에 의한 폐암 치료 방법
TW202612729A (zh) 涉及抗ｈｌａ－ｇ抗體及抗ｅｇｆｒ抗體以及抗ｐｄ－１抗體之組合療法
CN119300862A (zh) 包含抗ctla4和抗pd1的混合抗体的药物组合物及其治疗用途
HK40063551A (en) Method and medicament for treating cancer unresponsive to pd-1/pd-l1 signaling inhibitor
TW202604568A (zh) 使用抗ｐｄ－１抗體與抗ｃｔｌａ－４抗體之組合以治療肺癌

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40106641

Country of ref document: HK

SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination